the quest for an hiv vaccine

The quest for an HIV-1 therapeutic vaccine.

The hallmark of acute HIV-1 infection is overwhelming viral replication in CD4 + T cells that results in high levels of viremia. The initial peak of viral replication begins to decline simultaneously with the appearance of HIV-1–specific T cells, implicating the strong antiviral activity of these responses during acute infection [1, 2]. Several recent studies have demonstrated that the function...

The quest for GAS vaccine

The pursuit of a safe vaccine against Streptococcus pyogenes (group A streptococcus, GAS) that does not induce autoimmune pathology and that affords coverage for most GAS serotypes, has been a major goal for several decades. These infections account for over 500,000 premature deaths every year resulting from deep tissue infections and post-streptococcal autoimmune sequelae. Despite substantial ...

The Quest for an HIV-1 Vaccine Adjuvant: Bacterial Toxins as New Potential Platforms

While tremendous efforts are undergoing towards finding an effective HIV-1 vaccine, the search for an HIV-1 vaccine adjuvant lags behind and is understudied. More recently, however, efforts have focused on testing adjuvant formulations that can boost the immune response and generate broadly neutralizing antibodies to HIV-1 ENV (gp160). Despite this, there remain a number of challenges towards a...

The quest for a H1N1 flu vaccine.

Hope for HIV control in southern Africa: The continued quest for a vaccine

In a Perspective, Linda-Gail Bekker and Glenda Gray discuss HIV vaccine development.

Prospecting for an HIV vaccine

Human immunodeficiency virus (HIV) sets several challenges for the development of a preventative HIV vaccine. Predictable, protective natural immunity against HIV does not occur and so unlike most other diseases for which vaccines exist, there are few guideposts from natural infection. Nonetheless, six vaccine efficacy trials have occurred. One in particular, the Thai trial called RV144, showed...